ReviewJournal of diabetes2025

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.

Jimmy Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.